Advances in Therapy

, Volume 26, Issue 2, pp 155–169 | Cite as

Telbivudine in the treatment of chronic hepatitis B

  • Kathryn NashEmail author



The treatment of chronic hepatitis B virus (HBV) infection has been revolutionized in the past decade by the increased availability of effective antiviral agents. Telbivudine is an L-nucleoside that is structurally related to lamivudine and has recently been approved for use in patients with chronic HBV infection. Telbivudine is highly selective for HBV DNA and inhibits viral DNA synthesis with no effect on human DNA or other viruses. This article reviews the pharmacology, pharmacokinetics, therapeutic efficacy and safety of telbivudine, and discusses its place in the current armamentarium against HBV.


Relevant publications were identified from searches of Medline and PubMed between 2000 and 2008, using the search terms “hepatitis B/HBV,” “telbivudine/LdT,” “β-L-thymidine,” “pharmacokinetics,” “safety,” “adverse events,” and “resistance.” The reference lists of retrieved articles were searched for relevant studies.


Phase 3 clinical studies demonstrate that telbivudine is superior to lamivudine over a 2-year period in hepatitis B e-antigen (HBeAg)-positive and HBeAg-negative patients. Telbivudine was associated with a statistically signficantly greater reduction in HBV DNA, greater proportion of alanine aminotransferase normalization, and greater histological response than lamivudine. Furthermore, telbivudine use resulted in fewer cases of treatment failure and less virological resistance than lamivudine. However, after 2 years of therapy, telbivudine resistance was appreciable (25%) and considerably higher than that seen with other new antivirals such as tenofovir and entecavir. Overall, telbivudine was found to be safe, although grade 3 or 4 adverse events, including elevations in creatine kinase, were more commonly found in patients receiving telbivudine than lamivudine. Telbivudine is not active against lamivudine-resistant HBV.


Telbivudine is a new antiviral agent joining the armamentarium against HBV. It is superior to lamivudine in terms of therapeutic response and resistance profile. However, concerns about resistance with long-term use, along with inferior cost-effective analyses, have relegated telbivudine to a second-line agent in the management of chronic HBV infection.


hepatitis B resistance telbivudine treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maynard JE. World-wide control of hepatitis B. Int J Epidemiol. 1984;13:406–407.PubMedCrossRefGoogle Scholar
  2. 2.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.PubMedCrossRefGoogle Scholar
  3. 3.
    Lai C, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–2094.PubMedCrossRefGoogle Scholar
  4. 4.
    Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis e-antigenpositive chronic hepatitis B. A meta analysis. Ann Intern Med. 1993;119:312–323.PubMedGoogle Scholar
  5. 5.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695.PubMedCrossRefGoogle Scholar
  6. 6.
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745.PubMedCrossRefGoogle Scholar
  8. 8.
    Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis. 1992;10:46–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:673–676.Google Scholar
  10. 10.
    Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31:1037–1044.PubMedCrossRefGoogle Scholar
  11. 11.
    Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem specimens. N Engl J Med. 1981;305:1067–1076.PubMedGoogle Scholar
  12. 12.
    Newbold JE, Xin H, Tencza, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69:3350–3357.PubMedGoogle Scholar
  13. 13.
    Tuttleman JS, Porcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986;47:451–460.PubMedCrossRefGoogle Scholar
  14. 14.
    Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol. 2007;23:263–267.PubMedCrossRefGoogle Scholar
  15. 15.
    Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696.PubMedCrossRefGoogle Scholar
  16. 16.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastorenterology. 2006;131:1743–1751.CrossRefGoogle Scholar
  17. 17.
    Colonno RJ, Rose RE, Pokornowski, et al. Four year assessment of entecavir resistance in nucleosidenaïve and lamivudine refractory patients. Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain.Google Scholar
  18. 18.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.PubMedCrossRefGoogle Scholar
  19. 19.
    Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12(suppl. 1):119–129.PubMedGoogle Scholar
  20. 20.
    Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of beta-L-thymidine and beta-l-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis b virus. Antimicrob Agents Chemother. 2002;46:1728–1733.PubMedCrossRefGoogle Scholar
  21. 21.
    Seifer M, Patty A, Dukhan D, et al. Telbivudine (LdT) preferentially inhibits second (+) strand HBV DNA synthesis. J Hepatol. 2005;42(suppl. 2):151. Abstract 412.Google Scholar
  22. 22.
    Bryant ML, Bridges EG, Placidi L, et al. Antiviral Lnucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 2001;45:229–235.PubMedCrossRefGoogle Scholar
  23. 23.
    Cretton-Scott E, Zhou XJ, Bridges EG, et al. Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine in woodchucks and monkeys. Antivir Ther. 1999;4:A124.Google Scholar
  24. 24.
    Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration. J Clin Pharmacol. 2006;46:999–1007.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother. 2006;50:1721–1726.PubMedCrossRefGoogle Scholar
  26. 26.
    Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol. 2006;46:275–281.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAgpositive patients with chronic hepatitis B virus infection. Hepatology. 2004;40:719–726.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B infection: pharmacodynamic implications. Antimicrob Agents Chemother. 2006;50:874–879.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2007;51:4231–4235.PubMedCrossRefGoogle Scholar
  30. 30.
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536.PubMedGoogle Scholar
  31. 31.
    Lai CL, Leung N, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs. lamivudine vs. combination treatment in hepatitis B patients: two-year results. Gastroenterology. 2005;128(suppl. 2):A–692. Abstract 320.Google Scholar
  32. 32.
    Lai CL, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588.PubMedCrossRefGoogle Scholar
  33. 33.
    Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology. 2006;44(suppl. 1):222A. Abstract 91.Google Scholar
  34. 34.
    Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495.PubMedCrossRefGoogle Scholar
  35. 35.
    Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized double-blind trial. Hepatology. 2008;47:447–454.PubMedCrossRefGoogle Scholar
  36. 36.
    Jia JD, Hou JL, Yin YK, et al. Two year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J Hepatol. 2007;46(suppl. 1):S190. Abstract 497.Google Scholar
  37. 37.
    Heathcote EJ, Chan HL, Cho M, et al. A randomized trial of telbivudine (LdT) vs adefovir for HBeAg-positive chronic hepatitis B: results of the primary 24 week analysis. Gastroenterology. 2006;130(suppl. 2):A765.Google Scholar
  38. 38.
    Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med. 2007;147:745–754.PubMedGoogle Scholar
  39. 39.
    Shi KQ, Zhang DZ, Guo SH, et al. Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2008;16:641–645.PubMedGoogle Scholar
  40. 40.
    Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008;52:2521–2528.PubMedCrossRefGoogle Scholar
  41. 41.
    Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside analogue therapy. J Infect Dis. 2000;181:713–716.PubMedCrossRefGoogle Scholar
  42. 42.
    Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to lamivudine and adefovir. Hepatology. 2005;41:1391–1398.PubMedCrossRefGoogle Scholar
  43. 43.
    Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498–3507.PubMedCrossRefGoogle Scholar
  44. 44.
    Villet S, Pichoud C, Ollivet A, Villeneuvre J, Trepo C, Zoulim F. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology. 2005;42(suppl.):581A.Google Scholar
  45. 45.
    Gisg RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444.CrossRefGoogle Scholar
  46. 46.
    Bartholomeusz A, Yuen L, Locarnini S, et al. Understanding HBV resistance to telbivudine: molecular modelling and database mining. J Hepatol. 2007;46(suppl. 1)S185. Abstract 486CrossRefGoogle Scholar
  47. 47.
    Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro crossresistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81:147–155.PubMedCrossRefGoogle Scholar
  48. 48.
    Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial. J Hepatol. 2006;44(suppl. 2): S191. Abstract 514.CrossRefGoogle Scholar
  49. 49.
    Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451.PubMedCrossRefGoogle Scholar
  50. 50.
    Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702–3710.PubMedCrossRefGoogle Scholar
  51. 51.
    Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother. 2006;50:2309–2315.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhou X, Pietropaolo K, Becker M, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir. Gastroenterology. 2007;132(suppl. 2):A–766. Abstract S1782.Google Scholar
  53. 53.
    Zhou XJ, Fielman B, Dubuc-Patrick G, Chao G, Brown N. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects. J Hepatol. 2006;44(suppl. 2):S194. Abstract 522.CrossRefGoogle Scholar
  54. 54.
    Wong JB, Pauker SG. Cost effectiveness of telbivudine versus lamivudine for chronic hepatitis B. J Hepatol. 2007;46(suppl. 1):S199. Abstract 522.CrossRefGoogle Scholar
  55. 55.
    Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26:937–949.PubMedCrossRefGoogle Scholar
  56. 56.
    National Institute for Health and Clinical Excellence. Hepatitis B — telbivudine. Telbivudine for the treatment of chronic hepatitis B. Technology appraisal TA154. August 2008. Available at: www. Accessed December 1, 208.Google Scholar
  57. 57.
    Keeffe EB, Dieterich DT, Han SH, et al.. A treatment algorithm for the management of chronic hepatitis B infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341.PubMedCrossRefGoogle Scholar
  58. 58.
    EASL Clinical practice guideline: management of chronic hepatitis B. J Hepatol. In press.Google Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  1. 1.Southampton University Hospitals Trust, Southampton General HospitalSouthamptonUK

Personalised recommendations